NICE Approves Lucentis for Treatment of Myopic CNV

Medical News Today reports that "in a Final Appraisal Determination (FAD) published October 25, The National Institute for Health and Care Excellence (NICE) has recommended that Lucentis (ranibizumab) be approved for use within the NHS in England and Wales as an option to treat people with visual impairment due to choroidal neovascularisation associated with pathological myopia (myopic CNV)6. Myopic CNV is the growth of abnormal leaky blood vessels in the back of the eye in high myopia (severe near sightedness)." Read more.